SIR -Brain-derived neurotrophic factor (BDNF) is a neurotrophin important for neuronal development and synaptic plasticity. 1 However, it has also been recently implicated in the etiology and treatment of psychiatric disorders, including schizophrenia. 2 Indeed, neurodevelopmental theories of schizophrenia postulate that defects associated with the disease originate from abnormalities in brain development, 2 a process that is highly dependent on neurotrophic factors. Nevertheless, an imbalance in the homeostasis of the dopaminergic system is still considered central to the disease: defects in dopaminergic neurotransmission may represent a consequence of developmental events, but may also produce abnormalities in brain maturation. Since the dopamine transporter (DAT) is an important player in regulating dopaminergic neurotransmission, mice lacking DAT, as obtained by homologous recombination, 3 display several physiological changes culminating in a persistently activated dopaminergic tone, and may represent a useful model to investigate the molecular consequences of hyperdopaminergia. 4 We therefore used DAT knockout mice (DAT À/À) to investigate the consequences of dysregulated dopaminergic neurotransmission on BDNF expression, during development as well as in adulthood. In fact, BDNF is important for the development of dopaminergic system as well as for its function and plasticity in the mature brain.
We focused our analysis on BDNF expression in the frontal cortex for two reasons: first, this region is highly innervated by dopaminergic projections from ventral mesencephalon and, second, anatomical alterations at this level have been reported in schizophrenic patients. 5 Total RNA was extracted according to standard procedures and BDNF mRNA levels were investigated by RNase protection assay, using GAPDH as internal standard as previously described. 6 Statistical analysis was performed by Student's t-test (developmental experiments) or twoway ANOVA (stress experiments) followed, when necessary, by Single Contrast Post Hoc test.
The mRNA levels for BDNF and its high-affinity receptor Trk-B were significantly reduced by 70 and 40%, respectively, in the frontal cortex of DAT À/À at postnatal day 15 (PND 15) (Figure 1a ). The reduction of BDNF mRNA levels persisted at PND 30 and into adulthood (PND 60) (À50%), whereas Trk-B gene expression no longer differed from DAT þ / þ mice.
These data suggest that DAT removal may interfere with the late stage of cortical development through an impairment of BDNF expression and signaling (Trk-B reduction). The downregulation of the neurotrophin expression persists in adult mice and may lead to a reduction in synaptic plasticity.
It is possible that dopamine uptake in frontal cortex may depend, to some degree, on the norepinephrine transporter 7 probably due to its higher expression with respect to DAT. However, no alterations in the tissue levels of norepinephrine in frontal cortex were observed in DAT À/À mice (RR Gainetdinov and MG Caron, personal communication). Thus, it is likely that altered homeostasis of dopamine, rather than norepinephrine, may be responsible for the reduced BDNF mRNA levels in the frontal cortex of DAT À/À mice.
Dysfunction of DA system may also predispose to higher vulnerability under challenging events. 8 In order to address this issue, adult þ / þ or À/À DAT mice were exposed to a chronic restraint stress (30 min twice a day, lasting for 14 days): when compared to the nonstressed counterparts, BDNF mRNA levels were reduced after stress only in DAT þ / þ (F 1,15 ¼ 338.798; P ¼ 0.00006; SCPHT), but not in DAT À/À animals (F 1,15 ¼ 2.005; P ¼ 0.235; SCPHT) (Figure 1b) . Hence, stress is not able to exacerbate the basal deficit of BDNF expression in mutant mice indicating that DAT deletion may produce a situation similar to chronic stress, in analogy to what we have recently shown following maternal deprivation. 9 Alternatively, intact DAT may be required to determine the downregulation of cortical BDNF expression following chronic stress.
Reduced levels of BDNF in frontal cortex may endanger neuronal viability in other structures, such as the striatum, where BDNF is anterogradely transported. The reduced BDNF levels in frontal cortex may partly explain the striatal neurodegeneration sporadically observed in DAT -/-mice. 10 In conclusion, our findings indicate that genetic dysfunction of the dopaminergic system may lead to an early as well as long-lasting reduction in cortical BDNF expression, which can be detrimental for brain maturation and may yield a persistent impairment in synaptic plasticity. SIR -The potential role of the functional polymorphism in the regulatory region of the serotonin transporter gene (5-HTTLPR) in suicidal behavior has been a matter of controversy. Since suicidal behavior is a complex, multideterminated phenomenon, we hypothesized that the conflicting results may be explained by differences in characterization of suicide attempts. Thus, a detailed phenotypic characterization of the suicide attempt is of major interest given that a biological factor could play a major role in some categories of suicidal behavior (eg violent or impulsive or more lethal or repetitive ones) but not in every one. We have previously found an association between lower serotonergic function and suicidal behavior in major depressed 1 and schizophrenic patients. 2 Thus, to test this hypothesis we investigated the 5-HTTLPR polymorphism in a well-characterized sample of in-patients, subgrouped according to lifetime suicide behavior characteristics and in a sample of healthy controls.
Patients with consecutive admissions, diagnosed according to the DSM-IV criteria based on a structured interview, 3 with recurrent major depression (n ¼ 106) or schizophrenia (n ¼ 131) were enrolled. Healthy controls, without history of suicide, (n ¼ 75, staff or faculty members) were interviewed and were free of psychiatric illness, with no familial history of axis I psychiatric disorder up to first-degree relatives.
Suicide history was assessed using a semistructured interview 1,2 and a review of medical records. At least one close relative member was interviewed. This is important because a significant degree of past suicidal behavior may not be recorded during routine clinical assessment. 4 Furthermore, we evaluated, for the most lethal lifetime suicide attempt; the lethality, using the Lethality Rating Scale (LRS), scored 0-8, 1, 2 with a score of 3 or greater as a cutoff point; the intention with the Suicide Intent Scale (SIS); 5 and the methods, classified as nonviolent (drug overdose) or violent (cutting beyond a superficial scratch, jumping from a height, shooting, hanging).
Differences in genotype were calculated by w 2 test. Difference between groups was tested with Student's t-test. Odds ratio with 95% confidence intervals was calculated using Wolf's method. Tests were two-tailed and results significant when Pr0.05.
Genotyping was performed as previously reported. 6 There was no significant difference among healthy controls, schizophrenic and depressed patients in genotypic frequencies (w 2 ¼ 0.544, d.f. ¼ 4, P ¼ 0.969) or in demographic parameters (sex, age, race). They
